
News|Podcasts|September 6, 2024
Beyond the Birthrate: The Societal Costs of Maternal Mortality
Author(s)Miranda Schmalfuhs
Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Advertisement
Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon discusses:
- The broader societal implications of these maternal health issues highlighted in The Commonwealth Fund study
- The most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make
- Specific efforts Organon is undertaking to invest in research, education, and its pipeline to focus on critical areas of need in maternal health
- How her in-practice experience as an OB-GYN are informing Organon's strategic approach to addressing maternal health challenges
- and more!
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
EMD Serono Announces Agreement with Trump Administration Increasing Access to In Vitro Fertilization Therapies for US Patients
2
What Impact will TrumpRx and Other DTC Programs Have on Drug Availability?
3
Eli Lilly’s and Novo’s Stocks React to President Trump’s Comments on GLP-1 Prices
4
All of the Medications Announced as Part of FDA’s National Priority Voucher Program
5